Product Code: GVR-4-68039-467-3
U.S. Cancer Biopsy Market Growth & Trends:
The U.S. cancer biopsy market is expected to reach USD 20.18 billion by 2030, registering a CAGR of 11.12% from 2023 to 2030 according to a new report by Grand View Research, Inc. The growth of the U.S. cancer biopsy market is attributed to the rise in the adoption of biopsies based on multi-parametric magnetic resonance imaging and the increasing popularity of image-guided needle biopsies in precision medicine applications.
The liquid biopsy industry is anticipated to expand at an exponential rate in the coming years, wherein increasing investments and strategic initiatives by the companies involved in biopharmaceutical manufacturing & genomic data analysis are anticipated to play a central role. In April 2022, Global Brain invested in Craif, Inc. to develop a novel noninvasive urinary liquid biopsy for the early detection of cancer.
Furthermore, the advent of liquid biopsies, rising clinical implementation of biopsies, and advancements in quality & payment pertaining to genetic cancer diseases are the factors expected to boost the market growth in the coming years. The increasing prevalence of cancer and the growing geriatric population are also likely to fuel market growth.
Moreover, the advent of blood-based multi-cancer early detection (MCED) technologies is going to offer lucrative opportunities during the forecast period. MCED represents a paradigm shift in how cancers will be diagnosed and treated in the future. The great promise of MCED is that it will enable clinicians to convert from screening a few cancers to screening individuals for many cancers.
Companies such as GRAIL, Exact Sciences Corporation are developing MCED tests. In addition, the National Cancer Institute (NCI) is looking at ways to study and evaluate MCED tests. NCI is currently designing clinical trials & other research opportunities for MCED tests, and recently issued a request for information from test developers on their readiness to participate in research initiatives.
Key companies operating in the U.S. cancer biopsy market have adopted several strategic initiatives to reinforce their market presence. Major undertakings by the market participants are mergers & acquisitions, collaborations & partnerships, regional expansions, and new product launches. For instance, in April 2022, Medtronic entered into collaboration with GE Healthcare to address the increasing need for outpatient care. Under this initiative, customers can access financial solutions, extensive product portfolios, and exceptional services.
U.S. Cancer Biopsy Market Report Highlights:
- Fine-needle aspiration segment held a dominant share in 2022 owing to the effective and quick test for determining the status of uncertain tissue
- Pharma & biopharma discovery & development segment is projected to grow at the fastest rate during the forecast period owing to the increasing demand for developing novel drug candidates
- Breast cancer segment is the highest revenue-generating segment in the U.S. cancer biopsy market in 2022 owing to the increasing prevalence of breast cancer
- North America dominated the U.S. cancer biopsy market in 2022, which is attributed to preventive measures undertaken by the governments to stop the progression of diseases
Table of Contents
Chapter 1 Methodology and Scope
- 1.1 Research Methodology
- 1.2 Research Assumptions
- 1.2.1 Estimates And Forecast Timeline
- 1.3 Research Methodology
- 1.4 Information Procurement
- 1.4.1 Purchased Database
- 1.4.2 Gvr's Internal Database
- 1.4.3 Secondary Sources
- 1.4.4 Details Of Primary Research
- 1.5 Information Or Data Analysis
- 1.5.1 Data Analysis Models
- 1.5.1.1 End-Use Landscape Assessment
- 1.5.1.2 Market Origin Assessment
- 1.5.1.3 Oncology Diagnosis: Market Competition Analysis
- 1.6 Market Formulation And Validation
- 1.7 Model Details
- 1.7.1 Commodity Flow Analysis
- 1.7.1.1 Approach 1: Commodity Flow Approach
- 1.7.1.2 Approach 2: Country-wise market estimation using bottom-up approach
- 1.8 U.S. Market: CAGR Calculation
- 1.9 List of Secondary Sources
- 1.10 List of Primary Sources
- 1.11 Objectives
- 1.11.1 Objective 1
- 1.11.2 Objective 2
- 1.11.3 Objective 3
- 1.11.4 Objective 4
Chapter 2 Executive Summary
Chapter 3 Market Variables, Trends, and Scope
- 3.1 Cancer Medical Tourism Within & Outside the U.S.
- 3.2 Market Driver Analysis
- 3.2.1 Advent Of Liquid Biopsy
- 3.2.2 Transition Of Novel Oncology Diagnostics From Bench To Clinics
- 3.2.3 Advancements In Quality And Payment Pertaining To Genetic Cancer Tests
- 3.3 Market Restraint Analysis
- 3.3.1 Risks Associated With Biopsy Procedures
- 3.3.2 Technical And Clinical Challenges
- 3.4 Market Opportunity Analysis
- 3.4.1 Integral Role Of Biopsies In Oncology Companion Diagnostics
- 3.4.2 Increase In The Demand For Biopsies In Translational Research
- 3.5 Market Threat Analysis
- 3.5.1 Risk Associated With Repeat Biopsy Procedures
Chapter 4 Business Environment Analysis
- 4.1 SWOT Analysis; By Factor (Political & Legal, Economic, and Technological)
- 4.2 Porter's Five Forces Analysis
Chapter 5 Supply Chain Analysis
- 5.1 Sample Collection (List of Biobanks/Center)
- 5.2 Sample Processing (List of Vendors)
Chapter 6 Cost/Pricing Analysis
- 6.1 Biopsy Cost
- 6.1.1 By Indication
- 6.1.1.1 Typical Biopsy Costs For Patients Not Covered By Health Insurance In The U.S.
- 6.1.2 By Type/Method
- 6.2 Key Factors Influencing The Cost
- 6.3 Costs Of Cancer Management
- 6.3.1 Pharma Versus Diagnostics Price Analysis For Cancer Care
- 6.3.2 U.S. Expenditures For Cancer By Source Of Payment
- 6.3.2.1 Expenditures For Cancer Care By Year & Cancer Site, USD Million, 2010 - 2018
Chapter 7 Reimbursement And Regulatory Analysis
- 7.1 Regulatory Framework: U.S. Cancer Biopsy Market
- 7.2 Reimbursement Framework: U.S. Cancer Biopsy Market
Chapter 8 Challenges/Restraints/Complications Analysis
- 8.1 Challenges/Restraints/Complications Analysis
- 8.1.1 By Site (Organ)
- 8.1.2 By Method
Chapter 9 Cancer Biopsy Product Manufacturers
Chapter 10 Type Business Analysis
- 10.1 U.S. Cancer Biopsy Market: Type Movement Analysis
- 10.2 U.S. Cancer Biopsy Market: Comparative Analysis of Biopsy Type
- 10.3 Fine Needle Aspiration
- 10.4 Core Needle Biopsy (CNB)
- 10.4.1 U.S. Cancer Core Needle Biopsy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 10.4.1.1 U.S. Cancer Core Needle Biopsy Market Estimates And Forecasts For Pharma Use, 2018 - 2030 (USD Million)
- 10.4.1.2 U.S. Cancer Core Needle Biopsy Market Estimates And Forecasts For Clinical-Use, 2018 - 2030 (USD Million)
- 10.5 Cancer Surgical Biopsy
- 10.5.1 U.S. Cancer Surgical Biopsy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 10.5.1.1 U.S. Cancer Surgical Biopsy Market Estimates And Forecasts For Pharma Use, 2018 - 2030 (USD Million)
- 10.5.1.2 U.S. Cancer Surgical Biopsy Market Estimates And Forecasts For Clinical-Use, 2018 - 2030 (USD Million)
- 10.6 Skin Biopsy/Punch Biopsy
- 10.6.1 U.S. Cancer Fine Needle Aspiration (Fna) Biopsy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 10.6.1.1 U.S. Cancer Fine Needle Aspiration (Fna) Biopsy Market Estimates And Forecasts For Pharma Use, 2018 - 2030 (USD Million)
- 10.6.1.2 U.S. Cancer Fine Needle Aspiration (Fna) Biopsy Market Estimates And Forecasts For Clinical-Use, 2018 - 2030 (USD Million)
- 10.6.1.3 U.S. Skin Biopsy/Punch Cancer Biopsy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 10.6.1.4 U.S. Skin Biopsy/Punch Cancer Biopsy Market Estimates And Forecasts For Pharma Use, 2018 - 2030 (USD Million)
- 10.6.1.5 U.S. Skin Biopsy/Punch Cancer Biopsy Market Estimates And Forecasts For Clinical-Use, 2018 - 2030 (USD Million)
- 10.7 Others
- 10.7.1 U.S. Cancer Biopsy Market Estimates And Forecasts For Other Types, 2018 - 2030 (USD Million)
- 10.7.1.1 U.S. other types cancer biopsy market estimates and forecasts for pharma use, 2018 - 2030 (USD Million)
- 10.7.1.2 U.S. other types cancer biopsy market estimates and forecasts for clinical-use, 2018 - 2030 (USD Million)
Chapter 11 Site (Organ) Business Analysis
- 11.1 Cancer Biopsy Market: Site (Organ) Movement Analysis
- 11.2 Breast
- 11.2.1 U.S. Cancer Biopsy Market Estimates And Forecasts For Breast, 2018 - 2030 (USD Million)
- 11.3 Thyroid
- 11.3.1 U.S. Cancer Biopsy Market Estimates And Forecasts For Thyroid, 2018 - 2030 (USD Million)
- 11.4 Uterus & Cervix
- 11.4.1 U.S. Cancer Biopsy Market Estimates And Forecasts For Uterus & Cervix, 2018 - 2030 (USD Million)
- 11.5 Lung
- 11.5.1 U.S. Cancer Biopsy Market Estimates And Forecasts For Lung, 2018 - 2030 (USD Million)
- 11.6 Prostate
- 11.6.1 U.S. Cancer Biopsy Market Estimates And Forecasts For Prostate, 2018 - 2030 (USD Million)
- 11.7 Bladder
- 11.7.1 U.S. Cancer Biopsy Market Estimates And Forecasts For Bladder, 2018 - 2030 (USD Million)
- 11.8 Kidney
- 11.8.1 U.S. Cancer Biopsy Market Estimates And Forecasts For Kidney, 2018 - 2030 (USD Million)
- 11.9 Liver
- 11.9.1 U.S. Cancer Biopsy Market Estimates And Forecasts For Liver, 2018 - 2030 (USD Million)
- 11.10 Pancreas
- 11.10.1 U.S. Cancer Biopsy Market Estimates And Forecasts For Pancreas, 2018 - 2030 (USD Million)
- 11.11 Other Sites
- 11.11.1 U.S. Cancer Biopsy Market Estimates And Forecasts For Other Sites, 2018 - 2030 (USD Million)
Chapter 12 Application (Cause) Business Analysis
- 12.1 U.S. Cancer Biopsy Market: Application (Cause) Movement Analysis
- 12.2 Screening & Monitoring
- 12.2.1 U.S. Cancer Biopsy Market Estimates And Forecasts For Screening & Monitoring, 2018 - 2030 (USD Million)
- 12.3 Diagnostics
- 12.3.1 U.S. Cancer Biopsy Market Estimates And Forecasts For Diagnostics, 2018 - 2030 (USD Million)
- 12.4 Investigational & Translational Research
- 12.4.1 U.S. Cancer Biopsy Market Estimates And Forecasts For Investigational & Translational Research, 2018 - 2030 (USD Million)
- 12.5 Pharma & Biopharma Discovery & Development
- 12.5.1 U.S. Cancer Biopsy Market Estimates And Forecasts For Pharma & Biopharma Discovery & Development, 2018 - 2030 (USD Million)
Chapter 13 Regional Business Analysis
- 13.1 U.S. Cancer Biopsy Market: Regional Movement Analysis
- 13.2 U.S.
- 13.2.1 U.S. Cancer Biopsy Market, 2018 - 2030 (USD Million)
Chapter 14 Competitive Landscape
- 14.1 Market Participation Categorization
- 14.2 Strategy Framework
- 14.3 Vendor Landscape
- 14.3.1 List Of Key Distributors And Channel Partners
- 14.3.2 Key Customers
- 14.3.2.1 List Of Key Customers
- 14.3.3 Public Companies
- 14.3.3.1 List Of Public Companies
- 14.3.4 Private Companies
- 14.3.4.1 List Of Key Private Companies
- 14.3.5 Emerging Players
- 14.3.5.1 List Of Key Emerging Companies
- 14.4 Major Deals And Strategic Alliances Analysis
- 14.4.1 Mergers And Acquisitions
- 14.4.2 Collaborations And Partnerships
- 14.4.3 New Product Launch
- 14.5 Market Impact Analysis By Key Participants
- 14.5.1 Ansoff Matrix
- 14.5.2 Company/Competition Categorization (Primary & Secondary Market Participants)
Chapter 15 Company Profiles
- 15.1 Company Profiles
- 15.1.1 Bd (Becton, Dickinson And Company)
- 15.1.1.1 Company Overview
- 15.1.1.2 Financial Performance
- 15.1.1.3 Product Benchmarking
- 15.1.1.4 Strategic Initiatives
- 15.1.2 Izi Medical Products
- 15.1.2.1 Company Overview
- 15.1.2.2 Product Benchmarking
- 15.1.2.3 Strategic Initiatives
- 15.1.3 Johnson & Johnson Services, Inc.
- 15.1.3.1 Company Overview
- 15.1.3.2 Depuy Synthes
- 15.1.3.2.1 Company Overview
- 15.1.3.3 Ethicon, Inc.
- 15.1.3.3.1 Company Overview
- 15.1.3.4 Financial Performance
- 15.1.3.5 Product Benchmarking
- 15.1.4 Argon Medical
- 15.1.4.1 Company Overview
- 15.1.4.2 Product Benchmarking
- 15.1.4.3 Cook
- 15.1.4.4 Company Overview
- 15.1.4.5 Product Benchmarking
- 15.1.5 Spectra Medical Devices, Inc.
- 15.1.5.1 Company Overview
- 15.1.5.2 Product Benchmarking
- 15.1.6 Medtronic
- 15.1.6.1 Company Overview
- 15.1.6.2 Financial Performance
- 15.1.6.3 Product Benchmarking
- 15.1.6.4 Strategic Initiatives
- 15.1.7 Boston Scientific Corporation
- 15.1.7.1 Company Overview
- 15.1.7.2 Financial Performance
- 15.1.7.3 Product Benchmarking
- 15.1.7.4 Strategic Initiatives
- 15.1.8 Conmed Corporation
- 15.1.8.1 Company Overview
- 15.1.8.2 Financial Performance
- 15.1.8.3 Product Benchmarking
- 15.1.9 Inrad, Inc.
- 15.1.9.1 Company Overview
- 15.1.9.2 Product Benchmarking
- 15.1.10 Thermo Fisher Scientific, Inc.
- 15.1.10.1 Company Overview
- 15.1.10.2 Financial Performance
- 15.1.10.3 Product Benchmarking
- 15.1.10.4 Strategic Initiatives